We are live on ! Find out more
INO icon

Inovio Pharmaceuticals

213 hedge funds and large institutions have $724M invested in Inovio Pharmaceuticals in 2020 Q3 according to their latest regulatory filings, with 47 funds opening new positions, 88 increasing their positions, 48 reducing their positions, and 48 closing their positions.

New
Increased
Maintained
Reduced
Closed

83% more repeat investments, than reductions

Existing positions increased: 88 | Existing positions reduced: 48

70% more capital inflows, than outflows

Capital inflows: $186M | Capital outflows: $109M

13% more call options, than puts

Call options by funds: $117M | Put options by funds: $104M

1.45% more ownership

Funds ownership: 35.79% → 37.24% (+1.4%)

0% more funds holding

Funds holding: 212 → 213 (+1)

2% less first-time investments, than exits

New positions opened: 47 | Existing positions closed: 48

Holders
213
Holders Change
+1
Holders Change %
+0.47%
% of All Funds
4.28%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
47
Increased
88
Reduced
48
Closed
48
Calls
$117​M
Puts
$104​M
Net Calls
+$13​M
Net Calls Change
-⁠$26.6​M

INO Hedge Fund Activity: Q3 2020 in Review

213 of the 4,971 institutional investors tracked by Wall St. Rank reported a position in Inovio Pharmaceuticals (INO) for Q3 2020, worth a combined $724M — down 53% from $1.52B a quarter earlier.

Sellers outnumbered buyers: 48 funds closed out of INO and 47 opened new positions — a net loss of 1 holder — while 48 trimmed existing stakes and 88 added.

The largest buyer was Norges Bank, opening a new position worth an estimated $24.8M. The largest seller was ARK Investment Management, exiting entirely with an estimated $20.8M sold.

  • 213 institutional investors held Inovio Pharmaceuticals (INO) as of Q3 2020, up from 212 in Q2 2020.
  • Funds reported $724M of Inovio Pharmaceuticals stock for Q3 2020, down 53% quarter-over-quarter.
  • 47 funds opened new Inovio Pharmaceuticals positions in Q3 2020 and 48 closed out, a net change of -1 holder.
  • The largest Inovio Pharmaceuticals buyer in Q3 2020 was Norges Bank, an estimated $24.8M added.
  • The largest Inovio Pharmaceuticals seller in Q3 2020 was ARK Investment Management, an estimated $20.8M sold.

Based on aggregated 13F filings for Q3 2020.